[
  {
    "ts": null,
    "headline": "Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma",
    "summary": "WILMINGTON, Del., January 05, 2026--Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for DLBCL",
    "url": "https://finnhub.io/api/news?id=eff2fa59426d2affe6b6241f45a955e88033bb2ea9967374aaaafa8269636d40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767616200,
      "headline": "Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma",
      "id": 137991666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., January 05, 2026--Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for DLBCL",
      "url": "https://finnhub.io/api/news?id=eff2fa59426d2affe6b6241f45a955e88033bb2ea9967374aaaafa8269636d40"
    }
  }
]